Akebia Therapeutics (NASDAQ:AKBA) released its quarterly earnings data on Monday. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.61, Bloomberg Earnings reports. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%.
Akebia Therapeutics (NASDAQ:AKBA) opened at $13.52 on Tuesday. The firm has a market capitalization of $639.08, a price-to-earnings ratio of -4.28 and a beta of 0.80. Akebia Therapeutics has a twelve month low of $8.69 and a twelve month high of $20.25.
Several research firms recently issued reports on AKBA. ValuEngine cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Monday, November 13th. BTIG Research began coverage on Akebia Therapeutics in a report on Thursday, December 7th. They set a “buy” rating and a $30.00 price target on the stock. Piper Jaffray Companies began coverage on Akebia Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Mizuho reissued a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $22.20.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.